The Regional Health Authorities in Norway has recently decided to reimburse patients who are included in the first expansion cohort in IMPRESS-Norway according to the pay-for-performance model described below. IMPRESS-Norway is a precision medicine trial that tests approved drugs on new indications based on genetic changes in the patient’s tumor. The study started in April last year, and so far …
Collaboration with between countries is central for development of precision medicine projects. We are therefore grateful for the visit from our Swedish colleagues (Anders Edsjö, Ebba Hallersjö Hult, Maria Creignou, Mikaela Fridman, Päivi Östling, Richard Rosenquist Brandell and Simon Ekman) on Wedensday. The agenda for the visit included CONNECT, Testbed Sweden and Vision Zero Cancer, MegaLiT and IMPRESS-Norway, Genomic Medicine Sweden, SciLifelab and InPreD. …
Incyte Inc. has several relevant cancer drugs in its portfolio. Initially, Incyte will support IMPRESS with its drug Pemazyre. Pemazyre is a targeted drug that attacks fibroblast growth factor receptor 2 (FGFR2). The drug is currently approved for use in adults with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. FGFR2 fusions / …
IMPRESS-Norway started inclusion of patients 1. April 2021 and at the end of January 2022 50 patients have been offered treatment in a IMPRESS-Norway cohort and over 170 patients have been analyzed in National Molecular Tumor Board meetings.